The primary objective of the study was to assess the benefit of cytoreductive nephrectomy relative to immunotherapy regimens utilizing checkpoint inhibitors.
Kevin Wright
Advertisement
Articles by Kevin Wright
Olaparib has "ushered in the era of precision medicine in prostate cancer," said Maha Hussain, MD.
The app also provides patients with a socially distant alternative to in-person visits during the COVID-19 pandemic.
The majority of patients surveyed reported having at least some interest in sexual activity following surgery.
The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.
Advertisement
Latest Updated Articles
Sexual function continues after radical cystectomyPublished: December 3rd 2020 | Updated:
Analysis suggests survival improved when cytoreductive nephrectomy added to immunotherapy in mRCCPublished: December 15th 2020 | Updated:
Smartphone app may help implement ERAS protocols for radical cystectomyPublished: December 4th 2020 | Updated:
Enfortumab Vedotin shows robust survival outcomes in bladder cancerPublished: September 24th 2020 | Updated:
- Tivozanib May Be Superior Treatment for Patients With RCC, Study Finds
Published: May 29th 2020 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
